F. Hoffmann-La Roche V. Cipla Bolar Exemption Analysis.
F. Hoffmann-La Roche v. Cipla – Bolar Exemption Analysis
Court:
Delhi High Court, India
Citation:
F. Hoffmann-La Roche Ltd v. Cipla Ltd, CS(OS) No. 771/2008 (Delhi High Court)
Facts of the Case
Roche held a patent for Erlotinib, a cancer drug sold under the brand name Tarceva.
Cipla filed for manufacturing and marketing a generic version before the expiry of Roche’s patent.
Cipla argued that they were conducting tests and trials to comply with regulatory approval under India’s Section 107A of the Patents Act (Bolar exemption).
Legal Issue
Does the Bolar exemption (experimental use for regulatory approval) allow Cipla to manufacture and test a patented drug before patent expiry?
Can such pre-expiry activities be considered infringement under Indian patent law?
Delhi High Court Judgment
The court upheld Cipla’s argument, recognizing the Bolar exemption under Section 107A of the Indian Patents Act:
“It is not an infringement of patent rights to use the invention for purposes related to development and submission of information to the regulatory authorities required under any law in India for obtaining marketing approval.”
Roche’s claim of infringement was rejected because Cipla’s activities were limited to regulatory testing and pre-marketing preparation, not commercial sale.
Impact of the Case
Reinforced India’s commitment to the Bolar exemption for pharmaceuticals.
Encouraged generic manufacturers to prepare for market entry immediately after patent expiry.
Strengthened access to affordable medicines without violating patent rights.
Provided clarity for pre-launch regulatory testing under Section 107A.
Related Landmark Cases – Bolar Exemption & Generic Drugs
1. Roche v. Cipla (Erlotinib) – India (2008)
Facts:
Similar case where Roche challenged Cipla’s generic manufacturing for clinical trials.
Decision:
Reinforced that experimental and regulatory purposes are exempt under Section 107A.
Commercial sale before patent expiry remains infringement; only regulatory testing is allowed.
Impact:
Key precedent for generic manufacturers in India.
2. Merck Sharp & Dohme Corp v. Glenmark Pharmaceuticals Ltd – Sitagliptin (2013) – India
Facts:
Merck sued Glenmark for producing generic Sitagliptin before patent expiry. Glenmark relied on the Bolar exemption for regulatory tests.
Decision:
Delhi High Court allowed Glenmark to conduct regulatory testing, confirming Section 107A.
Commercial sale before expiry remained prohibited.
Impact:
Clarified scope of Bolar exemption in India for new drug applications.
3. Apotex Inc. v. Sanofi-Aventis (2008) – Canada
Facts:
Apotex manufactured generic drugs before patent expiry to submit data to Health Canada.
Legal Issue:
Does the Canadian Bolar exemption allow pre-expiry testing?
Decision:
Supreme Court of Canada confirmed regulatory testing exemption.
Generic manufacturers can use patented inventions solely for obtaining approval.
Impact:
Recognized pre-market testing without infringement in Canada.
4. Teva Pharmaceuticals v. Eli Lilly – India (Imatinib / Glivec, 2012)
Facts:
Teva sought to conduct clinical trials for generic Imatinib before patent expiry.
Decision:
Court applied Bolar exemption, allowing testing for regulatory compliance.
Sale before patent expiry was prohibited.
Impact:
Reinforced Bolar’s role in facilitating timely generic entry.
5. Roche Products Ltd v. Bolar Pharmaceuticals Ltd – USA (1984)
Facts:
Early US case where Bolar exemption was first recognized.
Generic company sought to prepare FDA approval data before patent expiry.
Decision:
Court confirmed that pre-marketing regulatory testing is not infringement.
Impact:
This inspired Bolar-type provisions in India and other jurisdictions.
6. Novartis AG v. Union of India – Section 3(d) and Bolar (2013)
Facts:
Novartis’ patent for Glivec was challenged for evergreening. Generic manufacturers invoked Bolar exemption to prepare for launch.
Decision:
Court recognized pre-expiry regulatory activities under Section 107A, but Novartis’ patent was rejected for evergreening.
Impact:
Highlighted intersection of patent validity and Bolar exemption.
Key Legal Principles – Bolar Exemption
| Principle | Explanation |
|---|---|
| Scope of Bolar | Experimental use solely for regulatory approval is exempt from infringement. |
| India | Section 107A of Patents Act allows pre-launch testing for approval. |
| Commercial Sale | Sale or distribution before patent expiry is infringement, not exempt. |
| Global Practice | Similar provisions exist in US, Canada, EU (regulatory testing exemption). |
| Generic Entry | Enables immediate market entry after patent expiry for affordable drugs. |
Conclusion
F. Hoffmann-La Roche v. Cipla is a landmark Indian case clarifying the scope of the Bolar exemption.
Indian courts consistently support generic manufacturers’ pre-launch regulatory testing without violating patents.
This principle is crucial for public health and affordable access to medicines.
Globally, similar Bolar exemptions exist in the US, Canada, and EU, facilitating timely generic entry.
RELATED Blog
comments